PromarkerEso clinical evidence
PromarkerEso’s ability to diagnose disease early in patients was validated in multiple clinical studies
In the primary clinical validation study, PromarkerEso showed accuracy of 94% in both determining patients as having EAC, or not having EAC. The area under the receiver operating characteristic curve (AUC) was 0.93, sensitivity 93.1%, with a low false positive rate (3.4%), and specificity 96.6% with high “rule-out” capability (NPV = 93.8%).
Poster. S. Bringans, J. Sheahan, K. Peters, I. Wang, M.N. Duong, G. Dhamrait, R. Lipscombe. 20thISDE World Congress for Esophageal Diseases in Edinburgh, Sep 2024.
This is the first application of the PromarkerD test for predicting kidney decline in type 1 diabetes and extend the clinical utility of PromarkerD beyond its original target population of adults with type 2 diabetes. The additional application for type 1 diabetes patients with their unique clinical needs offers a new target market for PromarkerD and addresses a critical health issue for over 537 million people worldwide who have diabetes, with type 1 diabetes representing 10% of all cases. The results of this were presented at the Australasian Diabetes Congress in August 2024 and have been accepted for publication in the journal of Clinical Diabetes and Endocrinology.
Poster.S. Bringans, E. Schoeman, N. Dorta Scott, R.Wang, P.Galettis R. Lipscombe. 29thAnnual Proteomics Lorne Symposium in Lorne, Australia, 31 January – 3 February 2024.
Retrospective analysis of blood samples from the completed clinical trial showed that patients predicted by PromarkerD to be at high-risk of chronic kidney disease were 13.5 times more likely than the low-risk group to develop the disease. The study provides international validation of previous findings that PromarkerD is able to correctly predict a clinically significant decline in kidney function up to four years in advance. The results were presented at the world’s leading diabetes conference, the 80th Scientific Sessions of the American Diabetes Association (ADA), June 2020 and 2022. Subsequently, the results were published in the Journal of Clinical Medicine.
Oral Presented by R. Lipscombe. R. Lipscombe M.N. Duong, R. Casey, G. Fernadez, S. Bringans, K. Peters, M.M. Hill, P. Tan, L. Chen.19th ISDE World Congress for Esophageal Diseases in Toronto, September 2023.
A.K Shah, G. Hartel, I. Brown, C. Winterford, R. Na, K. Le Cao, B.A. Spicer, M.A. Dunstone, W.A. Phillips, R.V. Lord, A.P. Barbour, D.I. Watson, V. Joshi, D.C. Whiteman, M.M. Hill; Mol Cell Proteomics 2018; 17(12): 2324–2334.
More information below
Find out how PromarkerEso can make the difference for you
Access the novel blood test that allows for the diagnosis of esophageal cancer to improve patient outcome
